Growth Metrics

Anika Therapeutics (ANIK) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $60.5 million.

  • Anika Therapeutics' Retained Earnings fell 3532.16% to $60.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.5 million, marking a year-over-year decrease of 3532.16%. This contributed to the annual value of $71.7 million for FY2024, which is 4403.29% down from last year.
  • Latest data reveals that Anika Therapeutics reported Retained Earnings of $60.5 million as of Q3 2025, which was down 3532.16% from $62.8 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Retained Earnings high stood at $231.4 million for Q3 2021, and its period low was $60.5 million during Q3 2025.
  • In the last 5 years, Anika Therapeutics' Retained Earnings had a median value of $197.6 million in 2023 and averaged $163.2 million.
  • As far as peak fluctuations go, Anika Therapeutics' Retained Earnings soared by 186.68% in 2021, and later plummeted by 5104.37% in 2024.
  • Anika Therapeutics' Retained Earnings (Quarter) stood at $225.6 million in 2021, then fell by 6.59% to $210.7 million in 2022, then crashed by 39.23% to $128.1 million in 2023, then tumbled by 44.03% to $71.7 million in 2024, then fell by 15.59% to $60.5 million in 2025.
  • Its Retained Earnings was $60.5 million in Q3 2025, compared to $62.8 million in Q2 2025 and $66.8 million in Q1 2025.